Effect of theCYP2C8Genotype on the Pharmacokinetics and Pharmacodynamics of Repaglinide
- 26 January 2011
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 39 (5), 927-932
- https://doi.org/10.1124/dmd.110.036921
Abstract
The pharmacokinetics of repaglinide shows pronounced interindividual variability, for which several reasons have been considered, including interactions with drugs inhibiting CYP2C8 and CYP2C8 genetic polymorphism. However, existing data on the role of genetic polymorphisms in repaglinide disposition are not fully consistent. We studied the effect of CYP2C8*3 on the pharmacokinetics and pharmacodynamics of repaglinide in 29 healthy whites carrying CYP2C8*3/*3 (n = 4), CYP2C8*1/*3 (n = 13), or CYP2C8*1/*1 (n = 12). After administration of a single dose of 2 mg of repaglinide, blood was drawn for assessment of repaglinide pharmacokinetics and pharmacodynamics, and urine was collected to quantify the main repaglinide metabolites M1 and M4 up to 24 h postdose. Repaglinide and the metabolites were quantified by liquid chromatography-tandem mass spectrometry. Considering only the effect of CYP2C8*3, the mean (95% confidence interval) area under the time-concentration curve (AUC) from zero to infinity of repaglinide was 72.4 (6.7–138.0), 97.2 (59.2–135.2), and 105.9 (52.4–159.3) ng · ml−1 · h and the maximal concentration (Cmax) was 38.5 (3.8–73.2), 50.3 (37.5–63.0), and 60.3 (31.5–89.1) ng · ml−1, respectively, in carriers of CYP2C8*3/*3, CYP2C8*1/*3, and CYP2C8*1/*1 [p > 0.05, one-way analysis of variance (ANOVA)]. In addition, for urinary metabolite excretion and pharmacodynamic parameters, i.e., mean and maximal changes in insulin and glucose concentration, no significant differences between CYP2C8 genotypes were observed. Likewise, no significant effects on the pharmacokinetics or pharmacodynamics were observed when AUC and Cmax of repaglinide were corrected for reported effects of the SLCO1B1 521T>C polymorphism or when both polymorphisms were tested in a two-way ANOVA. In conclusion, CYP2C8*3 does not seem to play an important role in the pharmacokinetics and pharmacodynamics of repaglinide given in a therapeutic dose.Keywords
This publication has 29 references indexed in Scilit:
- Cytochrome P450 2C8 Pharmacogenetics: A Review of Clinical StudiesPharmacogenomics, 2009
- Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian CancerBasic & Clinical Pharmacology & Toxicology, 2009
- Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleedingPharmacogenetics and Genomics, 2008
- Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of PaclitaxelClinical Cancer Research, 2005
- The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinideBritish Journal of Clinical Pharmacology, 2005
- Metabolism of Repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of Fibrates and RifampicinBasic & Clinical Pharmacology & Toxicology, 2005
- Detection of anti-diabetics in equine plasma and urine by liquid chromatography–tandem mass spectrometryJournal of Chromatography B, 2004
- CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinideBritish Journal of Clinical Pharmacology, 2003
- CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomesBiochemical Pharmacology, 2002
- Clinical Pharmacokinetics and Pharmacodynamics of RepaglinideClinical Pharmacokinetics, 2002